Condition
Fanconi Anemia Complementation Group A
Total Trials
4
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting3
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04437771Active Not RecruitingPrimary
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
NCT04248439Phase 2Active Not RecruitingPrimary
Gene Therapy for Fanconi Anemia, Complementation Group A
NCT04069533Phase 2Active Not RecruitingPrimary
Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A
NCT03814408Phase 1UnknownPrimary
A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A
Showing all 4 trials